← All trials
NCT06613763
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 11, 2024
- Primary completion
- Dec 30, 2024
- Completion date
- Mar 30, 2025
- First posted
- Sep 26, 2024
- Last posted
- Sep 26, 2024
- Enrollment
- 32
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Guangdong Raynovent Biotech Co., LtdLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.